None listed
Conditions
Brief summary
The study is a randomised, double-blind, parallel design, placebo-controlled study. The intervention will involve the consumption of MitoQ. Participants will be asked to visit the University of Auckland Grafton Campus on 6 occasions over a 3 week period. During visit 1, participants will have the study and PIS explained to them by the researcher and informed consent to participate in the trial will be obtained from those who meet the inclusion/exclusion criteria. Participants will be asked to complete a questionnaire to obtain a history of exercise and health and determine their eligibility to participate in the study. Participants will also be familiarised to the isokinetic dynamometer. Participants will be randomly assigned to receive one tablet per day containing either MitoQ (20 mg mitoquinol) or a placebo (tapioca powder, precipitated silica and microcrystalline cellulose 101) for 3 weeks. Following 2 weeks of supplementation, participants will return to the lab following an overnight fast to complete 300 maximal eccentric contractions of the knee extensors (20 sets of 15 with 30 seconds of rest between sets). Blood samples and measures of peak isometric, concentric and eccentric torque, muscle soreness and vertical jump performance will be taken before and immediately and 2, 24, 48, 72 and 168 hours after completion of the exercise. Participants will also collect all urine produced the day before, day of and day after the exercise. Partcipants will be asked to record all food intake using a food diary the day before, day of and day after exercise.
Interventions
The study is a parallel design study and participants will be randomly assigned to the MitoQ and placebo groups. Participants in the MitoQ group will consume one oral tablet containing 20 mg mitoquinol per day, for three weeks. Participants in the placebo group will also consume one oral tablet per day for three weeks, which will not contain mitoquinol. Following two weeks of supplementation with either MitoQ or placebo tablets, participants will complete a bout of eccentric exercise using thei
The study is a parallel design study and participants will be randomly assigned to the MitoQ and placebo groups. Participants in the MitoQ group will consume one oral tablet containing 20 mg mitoquinol per day, for three weeks. Participants in the placebo group will also consume one oral tablet per day for three weeks, which will not contain mitoquinol. Following two weeks of supplementation with either MitoQ or placebo tablets, participants will complete a bout of eccentric exercise using their knee extensor muscles on their dominant leg. Participants will perform 300 (20 sets of 15 repetitions separated by 30 seconds of rest) eccentric contractions using an isokinetic dynamometer and the exercise session will last 35 minutes. Participants will record their dietary intake using a food diary the day before, day of and day after the exercise bout. Participants will also collect all urine produced the day before, day of and day after exercise. Measures of muscle function and soreness will be measured before, immediately after, and 2, 24, 48, 72 and 168 hours post-exercise. Markers of exercise-induced oxidative stress will be measured in plasma samples collected before exercise and immediately and 2 hours post-exercise. Markers of exercise-induced oxidative stress will also be measured in urine samples collected the day before, day of and day after exercise. Adherence to the supplementation protocol will be measured by oversupplying the participants with tablets and counting how many are returned at the end of the trial.
Sponsors
University of Auckland
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
Male
Age
20 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
Male 20-35 years Sedentary to moderately active (no regular lower body resistance training in the previous 6 months) BMI between 18.5 and 30 kg/m2
Exclusion criteria
Allergies to nutritional supplement Taking medications which may affect exercise responses Any chronic or advance health conditions or injuries Smoking Antioxidant supplement intake within the previous 2 months Chronic disease
Outcome results
None listed